Active substanceAminocaproic acidAminocaproic acid
Similar drugsTo uncover
  • Aminocaproic acid
    solution d / infusion 
    ALIUM PFK, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
  • Aminocaproic acid
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    Avexima Sibir, OOO     Russia
  • Aminocaproic acid-SOLOfarm
    solution d / infusion 
    GROTEKS, LLC     Russia
  • Dosage form: & nbspsolution for infusions
    Composition:

    active substance: aminocaproic acid 50.0 g;

    Excipients: sodium chloride - 9.0 g; water for injection - up to 1.0 liter.

    Theoretical osmolarity is 690 mOsmol / l.

    Description:clear, colorless liquid.
    Pharmacotherapeutic group:hemostatic agent - fibrinolysis inhibitor
    ATX: & nbsp

    B.02.A.A.01   Aminocaproic acid

    Pharmacodynamics:The hemostatic agent inhibits the conversion of the fibrinolysin to the fibrinolysin, apparently due to inhibition of the activator of this process, and also has a direct inhibitory effect on fibrinolysin; inhibits the activating action of streptokinase, urokinase and tissue kinases on fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, reduces the permeability of capillaries. Has anti-allergic activity, improves the antitoxic function of the liver.
    Pharmacokinetics:With intravenous administration, the effect is manifested after 15-20 minutes. Absorption - high, Cmah -2 h, half-life (T1 / 2) -4 h. It is excreted by the kidneys - 40-60 % in unmodified form. If there is a violation of the excretory function of the kidneys, delayed excretion of aminocaproic acid occurs, and as a result, its concentration in the blood sharply increases.
    Indications:

    Bleeding (hyperfibrinolysis, hypo- and afibrinogenemia), bleeding during surgical interventions and pathological conditions, accompanied by increased fibrinolytic activity of the blood (with neurosurgical, intracavitary, thoracic, gynecological and urological operations, including prostate gland, lungs, pancreas; tonsillectomy, after dental interventions, in operations using the apparatus artificial circulation). Diseases of internal organs with hemorrhagic syndrome; premature detachment of the placenta, complicated abortion. Prevention of secondary hypofibrinogenemia in massive transfusions of canned blood.

    Contraindications:

    Hypersensitivity to the drug, hypercoagulation (thrombosis, thromboembolism), coagulopathy due to diffusion, disseminated intravascular coagulation (DVS-syndrome), propensity to thrombosis and thromboembolic diseases, kidney disease with impaired excretory function, hematuria, cerebral circulation disorders, pregnancy, lactation.

    Carefully:

    Arterial hypotension, valvular heart disease, hematuria, bleeding from the upper urinary tract of unknown etiology, liver failure, chronic renal failure (CRF), children under 1 year.

    Dosing and Administration:

    Intravenously, drip. If it is necessary to achieve a rapid effect (acute hypofibrinogenemia), inject up to 100 ml of 50 mg / ml solution at a rate of 50-60 drops per minute for 15-30 minutes. During the first hour, 4-5 g (80-100 ml) is administered and then, if necessary, 1 g (20 ml) every hour for about 8 hours or until the bleeding is completely stopped. In the case of ongoing or repeated bleeding, 50 mg / ml aminocaproic acid solution is repeated every 4 hours.

    Children, at the rate of 100 mg / kg - in 1 hour, then 33 mg / kg / h; the maximum daily dose is 18 g / m2. The daily dose for adults is 5-30 g. The daily dose for children under 1 year is 3 g; 2-6 years - 3-6 g; 7-10 years - 6-9 g, from 10 years - as for adults. In acute blood loss: children under 1 year - 6 g, 2-4 years - 6-9 g, 5-8 years - 9-12 g, 9-10 years - 18 g. Duration of treatment - 3-14 days.

    Side effects:

    Dizziness, tinnitus, headache, nausea, diarrhea, nasal congestion, skin rash, lowering of blood pressure (BP), orthostatic hypotension, convulsions, rhabdomyolysis, myoglobinuria,acute renal failure, subendocardial hemorrhage.

    Overdose:

    Increased side effects (dizziness, nausea, diarrhea, upper respiratory catarrh) and severe inhibition of fibrinolysis.

    In cases of overdose, it is advisable to inject plasminogen activators (streptokinase, urokinase or anestreptase).

    Interaction:

    Can be combined with the introduction of hydrolysates, glucose solutions (dextrose solutions), anti-shock solutions. In acute fibrinolysis, the administration of aminocaproic acid with a fibrinogen content of 2-4 g (maximal 8 g) must be supplemented by subsequent infusion.

    Antiaggregant decrease with simultaneous reception of anticoagulants of direct and indirect action.

    Do not add any medications to the aminocaproic acid solution.

    Special instructions:

    When prescribing the drug, it is necessary to monitor the fibrinolytic activity of the blood and the content of fibrinogen. With intravenous administration, coagulogram monitoring is necessary, especially in coronary heart disease, after a heart attack, and liver disease.

    Form release / dosage:

    Solution for infusions 50 mg / ml.

    Packaging:Solution for infusions of 50 mg / ml for 100, 250, 500 ml into polymeric containers for single-use infusion solutions made of polyolefin film. Each container is packaged in a secondary aluminum film bag. Instructions for use in a container with containers in an amount equal to the number of containers. Containers in the secondary packaging are placed in boxes of corrugated cardboard.
    Storage conditions:

    In dry, protected from light, out of reach of children, at a temperature of 2 to 25 ° C.

    Shelf life:

    3 years. Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-000249
    Date of registration:16.02.2011
    The owner of the registration certificate:FIRM MEDPOLIMER, JSC FIRM MEDPOLIMER, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp16.02.2011
    Illustrated instructions
      Instructions
      Up